佐力药业拟募15.56亿扩产加码主业 上市后累赚24.87亿分红率达57.96%

Core Viewpoint - Zhaoli Pharmaceutical plans to raise up to 1.556 billion yuan through the issuance of convertible bonds to support the expansion of its core business and innovation development [1][2] Group 1: Fundraising and Investment Plans - The company intends to use 1.09 billion yuan for the construction of an intelligent traditional Chinese medicine health factory (Phase I), 216 million yuan for the "Wuling + X" product development project, and 250 million yuan to supplement working capital [2] - This marks the company's first issuance of convertible bonds, which are considered a hybrid financing tool [2] - Since its IPO in 2011, the company has completed three rounds of equity financing, raising a total of 1.866 billion yuan [2] Group 2: Financial Performance - Zhaoli Pharmaceutical has seen steady growth in its core product sales, with cumulative net profit reaching 2.487 billion yuan since its listing [1][5] - For the first three quarters of 2025, the company's net profit was 510 million yuan, exceeding the total for the entire year of 2024, with a year-on-year growth of 21% [5] - The company's revenue increased from 1.091 billion yuan in 2020 to 2.578 billion yuan in 2024, with net profit rising from 89 million yuan to 508 million yuan during the same period [4] Group 3: Dividend Policy - The company has distributed a total of 1.442 billion yuan in dividends since its listing, with a dividend payout ratio of 57.96% [5] - In recent years, Zhaoli Pharmaceutical has increased its dividend payments, with payout ratios of 77.07%, 82.42%, and 81.82% from 2022 to 2024 [5]